This decision acknowledges evidence that the weight loss and metabolic improvement effects, proven in obesity treatment, also demonstrated clinical benefits in liver fibrosis and inflammation markers. This decision marks a turning point in the strategy of horizontally expanding the pipeline from obesity to liver disease, realizing Novo Nordisk's broader vision to dominate the metabolic disease hub with its wide patient base. While insurance and supply chain issues remain variables, the company's advantage in indication stacking over competitors is now clear. The industry anticipates that GLP-1's status as an anchor drug will be solidified in future integrated management models for co-morbid conditions (diabetes, cardiovascular, renal) associated with NASH/MASH. Due to the nature of accelerated approval, confirmatory trials (follow-up data from Phase 3 clinical trials) are required, and sustained efficacy, safety, and consistency between liver biopsy and non-invasive biomarkers in real-world use are key post-market checkpoints. Given the relatively distant pressure from generics and biosimilars in the GLP-1 category, accelerated profitability is also expected. Novo Nordisk is simultaneously pursuing indication expansion into areas such as cardiovascular disease, kidney disease, and sleep apnea. Amid rising regulatory and pricing policy risks (IRA, tariffs), an all-in-one metabolic platform is emerging as a key narrative from an investment perspective.